Table 2.

Main indices of T-cell-mediated immunity in patients with gastric cancer over the course of treatment (in percentage)

Patient group	Therapy stage	IL-2	TNFα	IFNγ
I-control (n=32)	29.6±0.4*	24.5±1.6	1.21±0.02*	54.6±0.6*
chemotherapy + surgery	26.4±0.8	23.6±1.3	1.11±0.01	50.4±0.6**
II-experimental (n=30)	29.7±0.5*	23.3±1.1	1.27±0.02*	52.2±0.5*
chemoimmunotherapy + surgery	28.2±0.5	22.7±1.5	1.25±0.01	50.6±0.9
In health (n=25)	46.3±0.7	21.4±0.3	2.16±0.08	67.7±0.8

^*difference between the index before treatment and in health is significant, p<0.05

^**difference between the index before and after treatment is significant, p<0.05

numerator-index before treatment, denominator-index after treatment